HUTCHMED (China) Limited (HCM)
HCMNASDAQ-GSBiotechnology: Pharmaceutical Preparations
$15.32
+0.1600 (+1.06%) today
Closed, Nov 9, 4:00 PM ET
- Market cap
- $2.67bn
- P/E
- –
- EPS, last 4 quarters
- –
- Dividend yield
- –
- Day range
- –
- 52-week range
- $9.77 to $16.33
- Average volume
- 69.6k
- Previous close
- $15.16
Analysts
1 coveringBuy1 buy, 0 hold, 0 sell
Targets a year out average $18.25, +19.1% from here
Earnings
Next report
Financials
| Quarter | Dec 2013 | Sep 2015 | Dec 2015 |
|---|---|---|---|
| Revenue | $36.55m | $39.44m | $56.28m |
| Gross profit | $25.35m | $10.04m | $24.84m |
| Operating income | -$13.20m | -$9.83m | $93.0k |
| Net income | $23.94m | -$11.31m | $3.36m |
News
8 latest- HUTCHMED (China) Limited Announces US FDA Orphan Drug Designation for Sovleplenib in Autoimmune Hemolytic AnemiaFintel · 5 days ago
- HUTCHMED's Sovleplenib Gets FDA Orphan Drug Status For Autoimmune Hemolytic Anemia RTTNews · 5 days ago
- HUTCHMED Advances ORPATHYS-TAGRISSO Through EU, Japan Reviews RTTNews · Nov 2, 2026
- HUTCHMED (China) Limited Announces Sovleplenib Granted US FDA Orphan Drug Designation for Primary Immune ThrombocytopeniaFintel · Oct 29, 2026
- HUTCHMED's Sovleplenib Receives U.S. FDA Orphan Drug Designation For ITP RTTNews · Oct 28, 2026
- HUTCHMED (China) Limited to Host Expert Webcast on Savolitinib Phase III Clinical DataFintel · Oct 27, 2026
- HUTCHMED Announces Positive Phase III Data for ORPATHYS plus TAGRISSO in SAFFRON and SANOVO Lung Cancer TrialsFintel · Oct 26, 2026
- AstraZeneca's Tagrisso Combo Achieves Significant Survival Benefit In Lung Cancer Trial; Stock Up RTTNews · Oct 26, 2026
The company
HUTCHMED (Nasdaq/AIM: HCM; HKEX: 13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Since inception it has focused on bringing drug candidates from in-house discovery to patients around the world, with its first four medicines marketed in China, the first of which is also approved around the world including in the US, Europe and Japan.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-GS
- Region
- Asia
- Website
- hutch-med.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.